SELLAS Life Sciences Group, Inc. (SLS)
USD 1.12
(0.9%)
USD 1.12
(0.9%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.41 Million | -23.8 Million | -26.02 Million | -10.41 Million | -17.64 Million | -30.42 Million |
| Net Income | -37.34 Million | -41.3 Million | -20.69 Million | -16.75 Million | -19.29 Million | -27.67 Million |
| Depreciation & Amortization | - | 457 Thousand | 5.68 Million | 282 Thousand | 1.69 Million | 3.75 Million |
| Deferred income taxes | - | -457 Thousand | -239 Thousand | -23 Thousand | -95 Thousand | -1.31 Million |
| Stock-based compensation | 2.09 Million | 1.72 Million | 1.01 Million | 578 Thousand | 573 Thousand | 395 Thousand |
| Change in working capital | 3.34 Million | 5.64 Million | -7.61 Million | 5.59 Million | -1.11 Million | -10 Million |
| Other non-cash items | 491 Thousand | 10.12 Million | -4.16 Million | -87 Thousand | 586 Thousand | 4.41 Million |
| Investing Cash Flow | -5.5 Million | -4.5 Million | - | - | - | - |
| Investments in PPE | -5.5 Million | -4.5 Million | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -5.5 Million | -4.5 Million | - | - | - | - |
| Financing Cash Flow | 22.31 Million | 24.07 Million | 12.07 Million | 38.44 Million | 19.56 Million | 23.12 Million |
| Debt repayment | - | - | - | - | - | -7.6 Million |
| Dividends payments | - | - | - | - | - | -487 Thousand |
| Common Stock Repurchased | -31 Thousand | - | - | - | - | - |
| Common Stock Issuance | 22.34 Million | 23.99 Million | 12.07 Million | 29.59 Million | 19.56 Million | 21.56 Million |
| Other Financing Activities | -31 Thousand | 85 Thousand | 12.07 Million | 8.84 Million | 19.56 Million | 9.64 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 2.3 Million | 1.21 Million | -2.51 Million | -836 Thousand | 12 Thousand | -7.93 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.04 Million | 4.42 Million | -5.1 Million | 6.42 Million | -1.12 Million | -2.07 Million |
| Cash at beginning of period | 17.22 Million | 21.45 Million | 35.4 Million | 7.37 Million | 5.45 Million | 12.75 Million |
| Cash at end of period | 2.63 Million | 17.22 Million | 21.45 Million | 35.4 Million | 7.37 Million | 5.45 Million |
| Capital Expenditure | -5.5 Million | -4.5 Million | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -14.59 Million | -4.23 Million | -13.94 Million | 28.02 Million | 1.92 Million | -7.29 Million |
| Free Cash Flow | -36.91 Million | -28.3 Million | -26.02 Million | -10.41 Million | -17.64 Million | -30.42 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7.47 Million | -9.56 Million | -8.13 Million | -37.34 Million | -9.26 Million | -8.84 Million |
| Depreciation & Amortization | - | - | - | - | - | 158 Thousand |
| Deferred income taxes | - | - | - | - | - | -158 Thousand |
| Stock-based compensation | 334 Thousand | 476 Thousand | 497 Thousand | 2.09 Million | 543 Thousand | 514 Thousand |
| Change in working capital | -2.68 Million | -1.8 Million | 2.68 Million | 3.34 Million | 1.71 Million | 604 Thousand |
| Other non-cash items | 1.53 Million | -1.19 Million | 127.99 Thousand | 491 Thousand | 122 Thousand | 156 Thousand |
| Investing Cash Flow | - | - | - | -5.5 Million | -3 Million | -2.5 Million |
| Investments in PPE | - | - | -5.5 Million | -5.5 Million | -3 Million | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 5.5 Million | -5.5 Million | -3 Million | -2.5 Million |
| Financing Cash Flow | 414 Thousand | 26.64 Million | 3.38 Million | 22.31 Million | 54 Thousand | -29 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -31 Thousand | -31 Thousand | 38 Thousand | -29 Thousand |
| Common Stock Issuance | 414 Thousand | 26.64 Million | 3.41 Million | 22.34 Million | 54 Thousand | -29 Thousand |
| Other Financing Activities | 414.00 | 26.64 Million | -31 Thousand | -31 Thousand | 54 Thousand | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -1.05 Million | 1.8 Million | 1.31 Million | 2.3 Million | 606 Thousand | 661 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -1.62 Million | -3.61 Million | 1.36 Million | 1.04 Million | 1.1 Million | -57 Thousand |
| Cash at beginning of period | 18.51 Million | 2.63 Million | 4.06 Million | 17.22 Million | 13.9 Million | 24 Million |
| Cash at end of period | 9.24 Million | 18.51 Million | 2.63 Million | 2.63 Million | 4.06 Million | 13.9 Million |
| Capital Expenditure | - | - | -5.5 Million | -5.5 Million | -3 Million | - |
| Effect of forex changes on cash | - | - | - | - | 3.37 Million | - |
| Net cash flow / Change in cash | -9.26 Million | 15.88 Million | -1.43 Million | -14.59 Million | -9.83 Million | -10.09 Million |
| Free Cash Flow | -9.68 Million | -10.76 Million | -10.32 Million | -36.91 Million | -9.89 Million | -7.56 Million |
TNPL
RADIOCITY
DECA
RAAJMEDI
ADDDF
DEUZF